A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer with histologic confirmation: ER+, HER2- invasive breast cancer (any PgR status) or poorly differentiated and/or invasive TNBC as defined by HER2-, ER-/PR- status, with Measurable disease by RECIST 1.1, or non measurable lytic, bone-only disease. Cannot have more than 1 chemo in metastatic setting.
Cheryl A. Young, RN, BSN
(410) 964-2212 ext 1137